Kandhasamy Sarkunam

This inventor holds 16 USPTO granted patents and 1 published patent application and 9 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kandhasamy Sarkunam. Retrieved from https://idiyas.com/inventor/kandhasamy-sarkunam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 1)

% Patents Active = 100.0

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Bengaluru, IN (2015)
Hosur, IN (2014 - 2024)

Company Filing History:

16 out of 3,742

Bristol-Myers Squibb Compnay

patents

Years Active: 2014-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492186 - BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS (2025-12-09),

2. 12319676 - Substituted amide compounds useful as farnesoid X receptor modulators (2025-06-03),

3. 12286428 - Tricyclic heteroaryl compounds useful as IRAK4 inhibitors (2025-04-29),

4. 12227496 - Substituted bicyclic compounds as farnesoid X receptor modulators (2025-02-18),

5. 12030835 - Substituted amide compounds useful as farnesoid X receptor modulators (2024-07-09),

6. 11713312 - Substituted bicyclic compounds as farnesoid X receptor modulators (2023-08-01),

7. 11254663 - Substituted bicyclic compounds as farnesoid X receptor modulators (2022-02-22),

8. 10618903 - Heteroaryl substituted aminopyridine compounds (2020-04-14),

9. 10202390 - Heteroaryl substituted aminopyridine compounds (2019-02-12),

10. 9643999 - Hepatitis C virus inhibitors (2017-05-09),

11. 9580463 - Hepatitis C virus inhibitors (2017-02-28),

12. 9527885 - Hepatitis C virus inhibitors (2016-12-27),

13. 9499550 - Hepatitis C virus inhibitors (2016-11-22),

14. 9169252 - Heteroaryl substituted nicotinamide compounds (2015-10-27),

15. 8957203 - Hepatitis C virus inhibitors (2015-02-17),

Title: Innovations and Contributions of Kandhasamy Sarkunam

Introduction

Kandhasamy Sarkunam is a notable inventor based in Hosur, India, recognized for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, he has made remarkable advancements in drug development and therapeutic applications.

Latest Patents

Among his latest patents, Sarkunam has developed substituted amide compounds that serve as farnesoid X receptor modulators. These compounds are designed to modulate the activity of the farnesoid X receptor (FXR) and are useful in treating various diseases associated with FXR dysregulation, including pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders. Another significant patent involves tricyclic heteroaryl compounds that act as IRAK4 inhibitors. These compounds are aimed at treating, preventing, or slowing inflammatory and autoimmune diseases, as well as cancer.

Career Highlights

Sarkunam is currently employed at Bristol-Myers Squibb Company, where he continues to innovate and contribute to the pharmaceutical industry. His work focuses on developing new therapeutic agents that address critical health challenges.

Collaborations

Throughout his career, Sarkunam has collaborated with esteemed colleagues, including Kishore V Renduchintala and Pulicharla Nagalakshmi, who is a prominent woman in the field.

Conclusion

Kandhasamy Sarkunam's innovative work and numerous patents highlight his dedication to advancing medical science and improving patient outcomes. His contributions are invaluable to the pharmaceutical industry and the broader field of healthcare.

Profile summary based on public USPTO records.